Viewing nowCombinationTraglitin Combi Sustained Release Tablet 2.5/750 mg
Linagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 757.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.

MFDS item code 202400516 · Approved 2024.03.12 · Insurance code 671807880
Improvement of blood glucose control in patients with type 2 diabetes mellitus
This medication assists patients with type 2 diabetes in managing blood sugar levels more effectively while simultaneously adhering to dietary adjustments and exercise therapy. Linagliptin and metformin work together to help stabilize blood glucose levels and support the overall management of diabetes in patients. Therefore, this medication is used to improve blood sugar control in diabetic patients.
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and extended-release metformin hydrochloride 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse effects associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug as a 2.5/750 mg or 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000 mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's existing dose of metformin hydrochloride, according to the current treatment regimen. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's existing dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately if necessary. -When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the existing doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73m2]. In patients with moderate renal impairment (CKD stage 3A), with creatine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
This medication helps regulate blood sugar. However, it can very rarely cause a condition known as lactic acidosis, which can be life-threatening, so caution is required. This medication should not be used in certain patients. For example, individuals allergic to its components, those with type 1 diabetes, patients with severe renal impairment, or those with acute illnesses or heart and liver dysfunction should not receive this treatment. Additionally, this medication may cause hypoglycemia; therefore, special care should be taken when used with other hypoglycemic agents such as insulin or sulfonylureas, and dosage adjustments may be required. Patients with impaired renal function should have their renal function tested periodically before taking this medication, and those with severely reduced renal function should not take it. During the treatment with this medication, rare side effects such as pancreatitis (acute pancreatitis) or rare skin conditions like bullous pemphigoid may occur, so immediate consultation with a doctor is necessary if symptoms like abdominal pain or skin abnormalities appear. The metformin component can lower vitamin B12 levels; thus, regular monitoring of vitamin B12 is advisable for those on long-term treatment. This medication should be swallowed whole without chewing or breaking it as the tablet shell may pass in stools, which is normal. Furthermore, this medication may interact with other drugs; thus, if you are taking other medications, you must inform your doctor or pharmacist. It is advisable for pregnant or nursing women not to use this medication, and insulin treatment is recommended in cases where there is a plan for pregnancy or confirmed pregnancy. Elderly patients often have impaired renal function; hence, renal function should be assessed before taking this medication, monitored regularly, and typically, the maximum dosage is not utilized. In case of an overdose, measures should be taken to prevent absorption of the medication from the gastrointestinal tract, and treatment should be sought immediately in the event of lactic acidosis. Lastly, this medication should be kept out of reach of children and stored away from moisture, and it is advisable not to transfer it to another container.
Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemia, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, itching, erythema, rash, pemphigoid, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reactions, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer-type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, voice disorder, epistaxis, wet cough, runny nose, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, male-pattern baldness, hyperhidrosis, dermatitis, goiter, confusional state, nocturia, dermatitis, hypertension, benign prostatic hyperplasia, vitreous hemorrhage, erectile dysfunction, unstable angina
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture; thereby, it should be stored in a tightly closed container. Additionally, it is best to store it at room temperature between 1 degree Celsius and 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness over a longer period.
Biconvex oval-shaped sustained release film-coated tablet in light pink color
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 757.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Linagliptin Micronized 5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Bio Tech Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 757.5mg
Tablet · Prescription medication · Combination
Daewon Biotech Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Biotech Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.